BioWorld

March 25, 2008

Zogenix Eyes Public Markets, Files for Potential $86M IPO

Only days after the FDA accepted for review Zogenix Inc.'s new drug application for its needle-free sumatriptan candidate, the San Diego-based firm filed for an initial public offering. (BioWorld Today) Read More

Cytokinetics Sees Shares Rise on Positive Heart Drug Data

Parkinson's Treated with SCNT as Genomics Data Find Home

NewCo News: Influmedix Plans to Go Multiple Rounds With M Channel Target

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...